(79 days)
No
The device description and performance studies focus on the physical components, materials, and standard performance testing of a disposable insulin syringe. There is no mention of any computational or analytical capabilities, let alone AI/ML.
Yes
The device is described as an insulin syringe intended for the injection of insulin, which is a medical treatment. Therefore, its purpose is therapeutic.
No
Explanation: The device is described as a "disposable insulin syringe" intended for "manual aspiration of insulin, and for the injection of insulin." Its function is to deliver a substance, not to analyze or identify a medical condition.
No
The device description clearly outlines physical components (needle, piston, barrel, etc.) and materials, indicating it is a hardware device, not software-only.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for the manual aspiration and injection of insulin into the body. This is a direct medical intervention on a patient, not a test performed on a sample taken from the body to diagnose a condition.
- Device Description: The description details a syringe and needle, which are instruments for administering substances into the body.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, urine, tissue, etc.), detecting analytes, or providing diagnostic information.
- Performance Studies: The performance studies focus on the physical properties of the syringe and needle, sterilization, biocompatibility, and shelf life, which are relevant to a medical device for injection, not an IVD.
- Predicate Device: The predicate device is also a "Sterile Insulin Syringe for single use with fixed needle," further confirming its classification as a device for administration, not diagnosis.
IVD devices are specifically designed to perform tests on samples from the human body to provide information for diagnosis, monitoring, or screening. This device's function is to deliver a substance (insulin) into the body.
N/A
Intended Use / Indications for Use
The disposable insulin syringe is intended for medical purposes for the manual aspiration of insulin, and for the injection of insulin into parts of the body below the surface skin.
Product codes
FMF
Device Description
The Disposable Insulin Syringes are provided sterile, single use. For the Disposable Insulin Syringes, they consist of six components: (1) orange needle cap (2) needle (3) piston (4) plunger (5) barrel (6) orange protective end cap. The materials for all components are listed in Table 1 Component material list.
| Component | Material |
|---|---|
| Protective end cap | PE (polyethylene) |
| Plunger | PP (polypropylene) |
| Piston | Polysoprene |
| Barrel | PP (polypropylene) |
| Needle cap | PE (polyethylene) |
| Needle | 304 Stainless steel |
| Lubricant | Polydimethylsiloxane |
The Disposable Insulin Syringes are available in different combination of syringe volumes and needle sizes. The range of syringe volume, needle gauge and needle length are listed in Table 2 syringe and needle specification.
| Syringe volume | Needle gauge | Available Needle length |
|---|---|---|
| 0.3ml | 28G | 3/8", 1/2", 5/16"or 5/8" |
| 0.5ml | 29G | 3/8", 1/2", 5/16"or 5/8" |
| 1ml | 30G | 3/8", 1/2", 5/16"or 5/8" |
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non clinical tests were conducted to verify that the proposed device met all design specifications as was Substantially Equivalent (SE) to the predicate device. The test results demonstrated that the proposed device complies with the following standards:
- A ISO 9626:1991+AMENDMENT 1 2001 Stainless steel needle tubing for the manufacture of medical devices;
- ISO 8537: 2007 Sterile single-use syringes, with or without needle, for insulin; >
-
ISO 10993-7:2008 Biological evaluation of medical devices- Part 7: Ethylene oxide sterilization residuals;
-
ASTM F 88/F88M-09 Standard test method for seal strength of flexible barrier materials;
-
ASTM F1140/F1140M-13 Standard test methods for internal pressurization failure resistance of unrestrained packages;
- USP37-NF32 Bacterial Endotoxins Limit. A
-
ISO 11737-2:2009 Sterilization of medical devices- Microbiological methods- Part 2: Test of sterility performed in the definition, validation and maintenance of a sterilization process
-
ISO 11135-1:2007 Sterilization of health care products- Ethylene oxide- Part 1: Requirements for development, validation and routine control of a sterilization process for medical devices.
- ASTM F1886/F1886M-09 (Reapproved 2013), Standard Test Method For Determining > Integrity Of Seals For Flexible Packaging By Visual Inspection. (Sterility)
-
ASTM F1929-12, Standard Test Method For Detecting Seal Leaks In Porous Medical Packaging By Dye Penetration. (Sterility)
Biocompatibility conclusion:
The patient-contact materials of product components of the proposed device, Disposable Insulin Syringe, are identical to the patient-materials of product components of the legally marketed device, Syringes and Needles, as it was cleared in K113091, in 10/28/2011, which is also manufactured by Jiangyin Caina Technology Co., Ltd.
Although the proposed devices are insulin syringe, the previous devices are disposable syringe, however, their manufacturing process, including sterilization process, are exactly the same, and the intended application scope are both for hypodermically injection of fluid to human body.
The necessary tests for biocompatibility testing including Cytotoxicity, Sensitization, Irritation on Intracutaneous Reactivity, System Toxcity (Acute) and Haemo-compatiblity have been provided in K113091 Submission. And the biocompatibility test results can demonstrate the compatibility of all of the patient-contact materials of the proposed device meets the requirements of Biocompatibility.
Shelf life Conclusion:
A maximum shelf life of 5 years has been assigned to the proposed device, when stored unopened at ambient temperature, in dry conditions away from direct sources of light, in accordance with the manufacturer's recommendations. The shelf life is based on an assessment of the seal integrity of the sterile barrier packaging after accelerated aging, performance testing of device after accelerated aging and Sterility test after accelerated aging.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 880.5860 Piston syringe.
(a)
Identification. A piston syringe is a device intended for medical purposes that consists of a calibrated hollow barrel and a movable plunger. At one end of the barrel there is a male connector (nozzle) for fitting the female connector (hub) of a hypodermic single lumen needle. The device is used to inject fluids into, or withdraw fluids from, the body.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, stacked on top of each other.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
October 2, 2015
Jiangyin Caina Technology Company Incorporated c/o Mr. Mark Job Regulatory Technology Services, Inc. 1394 25th Street, NW Buffalo, MN 55313
Re: K151949
Trade/Device Name: Disposable Insulin Syringe Regulation Number: 21 CFR 880.5860 Regulation Name: Piston Syringe Regulatory Class: II Product Code: FMF Dated: September 14, 2015 Received: September 18, 2015
Dear Mr. Job:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Page 2 - Mr. Mark Job
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Tina Kiang -S
for Erin I. Keith, M.S. Director Division of Anesthesiology, General Hospital, Respiratory, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known)
Device Name Disposable Insulin Syringe
Indications for Use (Describe)
The disposable insulin syringe is intended for medical purposes for the manual aspiration of insulin, and for the injection of insulin into parts of the body below the surface skin.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ------------------------------------------------- | -- |
Prescription Use (Part 21 CFR 801 Subpart D)
X Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW *
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Exhibit 2 # 510(k) Summary
This 510(k) Summary is being submitted in accordance with requirements of Title 21 CFR Section 807.92.
The assigned 510(k) Number: _ K151949
-
- Date of Preparation: 9/8/2015
-
- Sponsor Identification
Jiangyin Caina Technology Co., Ltd. No.2, Taifu Road, Huashi Town, Jiangyin, Jiangsu, 214421, China
Establishment Registration Number: 3005670221
Contact Person: Jun Lu Position: General Manager Tel: +86-510-86205183 Fax: +86-510-86215183 Email: jun.lu@cainamedical.com
-
- Designated Submission Correspondent
Ms. Diana Hong (Primary Contact Person) Ms. Jing Cheng (Alternative Contact Person)
- Designated Submission Correspondent
Mid-Link Consulting Co., Ltd P.O. Box 120-119, Shanghai, 200120, China
Tel: +86-21-22815850, Fax: 240-238-7587 Email: info@mid-link.net
4
-
- Identification of Proposed Device
Trade Name: Disposable Insulin Syringe Common Name: Insulin syringe with needle
- Identification of Proposed Device
Regulatory Information Classification Name: Syringe, Piston Classification: II; Product Code: FMF Regulation Number: 21CFR 880.5860 Review Panel: General Hospital;
Intended Use Statement:
The disposable insulin syringe is intended for medical purposes for the manual aspiration of insulin, and for the injection of insulin into parts of the body below the surface skin.
Device Description
The Disposable Insulin Syringes are provided sterile, single use.
For the Disposable Insulin Syringes, they consist of six components: (1) orange needle cap (2) needle (3) piston (4) plunger (5) barrel (6) orange protective end cap. The materials for all components are listed in Table 1 Component material list.
| Component | Material |
|---|---|
| Protective end cap | PE (polyethylene) |
| Plunger | PP (polypropylene) |
| Piston | Polysoprene |
| Barrel | PP (polypropylene) |
| Needle cap | PE (polyethylene) |
| Needle | 304 Stainless steel |
| Lubricant | Polydimethylsiloxane |
Table 1 Component material list
The Disposable Insulin Syringes are available in different combination of syringe volumes and needle sizes. The range of syringe volume, needle gauge and needle length are listed in Table 2 syringe and needle specification.
5
| Syringe volume | Needle gauge | Available Needle length |
|---|---|---|
| 0.3ml | 28G | 3/8", 1/2", 5/16"or 5/8" |
| 0.5ml | 29G | 3/8", 1/2", 5/16"or 5/8" |
| 1ml | 30G | 3/8", 1/2", 5/16"or 5/8" |
Table 2 the range of syringe volume, needle gauge and needle length
- Identification of Predicate Device న్.
510(k) Number: K072739 Product Name: Sterile Insulin Syringe for single use with fixed needle
Manufacturer: ShanDong Weigao Group Medical Polymer Products Co., Ltd
-
Identification of Reference Device 6.
510(k) Number: K113091 Product Name: Syringe and Needles Manufacturer: Jiangyin Caina Technology Co., Ltd -
- Non-Clinical Test Conclusion
Non clinical tests were conducted to verify that the proposed device met all design specifications as was Substantially Equivalent (SE) to the predicate device. The test results demonstrated that the proposed device complies with the following standards:
- Non-Clinical Test Conclusion
-
A ISO 9626:1991+AMENDMENT 1 2001 Stainless steel needle tubing for the manufacture of medical devices;
-
ISO 8537: 2007 Sterile single-use syringes, with or without needle, for insulin; >
-
ISO 10993-7:2008 Biological evaluation of medical devices- Part 7: Ethylene oxide sterilization residuals;
-
ASTM F 88/F88M-09 Standard test method for seal strength of flexible barrier materials;
-
ASTM F1140/F1140M-13 Standard test methods for internal pressurization failure resistance of unrestrained packages;
-
USP37-NF32 Bacterial Endotoxins Limit. A
-
ISO 11737-2:2009 Sterilization of medical devices- Microbiological methods- Part 2: Test of sterility performed in the definition, validation and maintenance of a sterilization process
-
ISO 11135-1:2007 Sterilization of health care products- Ethylene oxide- Part 1: Requirements for development, validation and routine control of a sterilization process for medical devices.
-
ASTM F1886/F1886M-09 (Reapproved 2013), Standard Test Method For Determining > Integrity Of Seals For Flexible Packaging By Visual Inspection. (Sterility)
-
ASTM F1929-12, Standard Test Method For Detecting Seal Leaks In Porous Medical
6
Packaging By Dye Penetration. (Sterility)
Biocompatibility conclusion:
The patient-contact materials of product components of the proposed device, Disposable Insulin Syringe, are identical to the patient-materials of product components of the legally marketed device, Syringes and Needles, as it was cleared in K113091, in 10/28/2011, which is also manufactured by Jiangyin Caina Technology Co., Ltd.
Although the proposed devices are insulin syringe, the previous devices are disposable syringe, however, their manufacturing process, including sterilization process, are exactly the same, and the intended application scope are both for hypodermically injection of fluid to human body.
The necessary tests for biocompatibility testing including Cytotoxicity, Sensitization, Irritation on Intracutaneous Reactivity, System Toxcity (Acute) and Haemo-compatiblity have been provided in K113091 Submission. And the biocompatibility test results can demonstrate the compatibility of all of the patient-contact materials of the proposed device meets the requirements of Biocompatibility.
Shelf life Conclusion:
A maximum shelf life of 5 years has been assigned to the proposed device, when stored unopened at ambient temperature, in dry conditions away from direct sources of light, in accordance with the manufacturer's recommendations. The shelf life is based on an assessment of the seal integrity of the sterile barrier packaging after accelerated aging, performance testing of device after accelerated aging and Sterility test after accelerated aging.
8. Clinical Test Conclusion
No clinical study is included in this submission.
7
Substantially Equivalent (SE) Comparison 9.
| Item | Proposed device | Predicate Device |
|---|---|---|
| Product | Disposable insulin syringe | K072739 |
| Sterile Insulin Syringe for single use with fixed needle | ||
| Product Code | FMF | FMF |
| Regulation Number | 21 CFR 880.5860 | 21 CFR 880.5860 |
| Intended Use | The disposable insulin syringe is intended for medical purposes for the manual aspiration of insulin, and for the injection of insulin into parts of the body below the surface skin. | The Sterile Insulin Syringe for single use with fixed needle is a device intended for medical purposes for the manual aspiration of insulin, and for the injection of insulin into parts of the body below the surface skin |
| Feature | Orange Needle cap, | |
| Fixed Needle; | ||
| Piston; | ||
| Plunger; | ||
| Barrel; | ||
| Orange Protective end cap | Orange Needle cap, | |
| Fixed Needle; | ||
| Piston; | ||
| Plunger; | ||
| Barrel; | ||
| Orange Protective end cap | ||
| Sterile | Yes | Yes |
| Single Use | Yes | Yes |
| Color Coding | Yes | Yes |
| Performance | ISO 9626:1991, AMENDMENT 1 2001 | |
| ISO 8537:2007 | Unknown | |
| Biocompatibility | Conforms to the requirement of ISO 10993 series Standards | Conforms to the requirement of ISO 10993 series Standards |
Table 1 Comparison between proposed device and predicate device
10. Substantially Equivalent (SE) Conclusion
Based on the comparison and analysis above, the proposed devices are determined to be Substantially Equivalent (SE) to the predicate device.